News Quantified

AVRO – avrobio, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure [Yahoo! Finance]

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CHRD, KAMN, CTLT, AVRO

Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm

Tectonic Therapeutic Announces Participation at Investor Conferences in March

Form EFFECT AVROBIO, Inc.

Form 424B3 AVROBIO, Inc.

Form S-4/A AVROBIO, Inc.

Form S-4/A AVROBIO, Inc.

Form 425 AVROBIO, Inc. Filed by: AVROBIO, Inc.

Top News Gainers

7/16 AVROBIO Announces Proposed Public Offering of Common Stock 23.8%

2/4 Avrobio Inc (NASDAQ: AVRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 16.9%

7/15 AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease 15.0%

8/8 Q2/2019 6/30/2019 EPS -0.670 ZacksConsensus -0.750 ActVsEst 0.080 - Beat 11.3%

2/4 AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020 11.1%

3/16 Form 10-K AVROBIO, Inc. For: Dec 31 9.9%

8/16 AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer 7.7%

1/15 Form EFFECT AVROBIO, Inc. 7.5%

6/26 Avrobio Inc (NASDAQ: AVRO) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 6.8%

4/17 Avrobio Inc (NASDAQ: AVRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.4%

Top News Decliners

3/16 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus N/A ActVsEst N/A - N/A -32.3%

2/12 AVROBIO Announces Proposed Public Offering of Common Stock -14.5%

4/1 Avrobio Inc (NASDAQ: AVRO) had its "buy" rating re-affirmed by analysts at Mizuho. -11.1%

9/27 Avrobio Inc (NASDAQ: AVRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. -10.0%

1/13 Form 8-K AVROBIO, Inc. For: Jan 13 -9.5%

2/14 Form SC 13G/A AVROBIO, Inc. Filed by: CITADEL ADVISORS LLC -7.3%

7/30 Form SC 13D AVROBIO, Inc. Filed by: Atlas Venture Fund X, L.P. -7.3%

3/6 Form 4 AVROBIO, Inc. For: Mar 04 Filed by: Avruch Steven -6.3%

3/30 AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact -5.9%

3/17 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day